thalidomide has been researched along with Glial Cell Tumors in 26 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG)." | 9.16 | A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. ( Case, D; Ellis, TL; Enevold, G; Lesser, GJ; McMullen, KP; McQuellon, RP; Rosdhal, R; Ruiz, J; Shaw, EG; Stieber, VW; Tatter, SB, 2012) |
| "A phase II study was conducted to assess the efficacy of administering daily thalidomide concomitantly with radiation and continuing for up to 1 year following radiation in children with brain stem gliomas (BSG) or glioblastoma multiforme (GBM)." | 9.12 | Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. ( Briody, C; Chi, S; Chordas, C; Goumnerova, LC; Kieran, MW; MacDonald, T; Marcus, KJ; Packer, RJ; Poussaint, TY; Scott, RM; Turner, CD; Ullrich, N; Vajapeyam, S; Zimmerman, MA, 2007) |
| " Our data demonstrate that thalidomide in combination with BCNU is well tolerated and has antitumor activity in patients with recurrent high-grade gliomas." | 9.10 | Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003) |
| "Thalidomide is a generally well-tolerated drug that may have antitumor activity in a minority of patients with recurrent high-grade gliomas." | 9.09 | Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000) |
| "The efficacy of thalidomide in terms of response in recurrent gliomas is low, with a partial response rate of only 6%." | 9.09 | Thalidomide as an anti-angiogenic agent in relapsed gliomas. ( Brada, M; Dowe, A; Gore, M; Hines, F; Short, SC; Traish, D, 2001) |
| "For its numerous abilities including sedation, we have been using thalidomide (TH) as the 'last therapeutic option' in patients with advanced gliomas." | 7.81 | Thalidomide as palliative treatment in patients with advanced secondary glioblastoma. ( Ackerl, M; Dieckmann, KU; Flechl, B; Hainfellner, JA; Hassler, MR; Marosi, C; Prayer, D; Preusser, M; Rössler, K; Sax, C; Woehrer, A, 2015) |
| "Human malignant glioma cells U251-MG were cultured and assigned to four groups with different treatments for 3 days: temozolomide group (100 micromol/L), thalidomide group (100 microg/L), temozolomide (100 micromol/L) plus thalidomide group (100 microg/L) and control group." | 7.75 | Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. ( Gao, S; Ji, YW; Pan, Q; Yang, XJ; Zhang, WG, 2009) |
| "The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma." | 7.73 | Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006) |
| "Serial MR imaging was performed in 18 consecutive patients with recurrent malignant gliomas receiving both thalidomide and carboplatin for 12-month periods." | 7.70 | Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. ( Cha, S; Glass, J; Gruber, ML; Johnson, G; Knopp, EA; Litt, A; Lu, S; Zagzag, D, 2000) |
| "Malignant gliomas are tumors with a very unfavorable prognosis." | 5.43 | Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas. ( Kramm, CM; Kühnöl, CD; Staege, MS, 2016) |
| "Gliomas are highly vascularized tumors, suggesting that the prevention of vessel formation by anti-angiogenic treatment might be effective." | 5.40 | Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. ( Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D, 2014) |
| "Thalidomide treatment also dramatically suppressed the anchorage-independent growth of U-87 MG and other glioma cells by over a thousand fold without affecting its anchorage-dependent growth, which may be accomplished by knocking down endogenous bFGF expression in these cells." | 5.35 | The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma. ( Mei, SC; Wu, RT, 2008) |
| "Thalidomide is a racemate with known pharmacologic and pharmacokinetic enantioselectivity." | 5.34 | Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. ( Boyle, FM; Davey, RA; Gu, XQ; Mather, LE; Murphy, S, 2007) |
| "Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies." | 5.33 | Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006) |
| "Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG)." | 5.16 | A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. ( Case, D; Ellis, TL; Enevold, G; Lesser, GJ; McMullen, KP; McQuellon, RP; Rosdhal, R; Ruiz, J; Shaw, EG; Stieber, VW; Tatter, SB, 2012) |
| "A phase II study was conducted to assess the efficacy of administering daily thalidomide concomitantly with radiation and continuing for up to 1 year following radiation in children with brain stem gliomas (BSG) or glioblastoma multiforme (GBM)." | 5.12 | Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. ( Briody, C; Chi, S; Chordas, C; Goumnerova, LC; Kieran, MW; MacDonald, T; Marcus, KJ; Packer, RJ; Poussaint, TY; Scott, RM; Turner, CD; Ullrich, N; Vajapeyam, S; Zimmerman, MA, 2007) |
| " Our data demonstrate that thalidomide in combination with BCNU is well tolerated and has antitumor activity in patients with recurrent high-grade gliomas." | 5.10 | Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003) |
| "Thalidomide is a generally well-tolerated drug that may have antitumor activity in a minority of patients with recurrent high-grade gliomas." | 5.09 | Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000) |
| "The efficacy of thalidomide in terms of response in recurrent gliomas is low, with a partial response rate of only 6%." | 5.09 | Thalidomide as an anti-angiogenic agent in relapsed gliomas. ( Brada, M; Dowe, A; Gore, M; Hines, F; Short, SC; Traish, D, 2001) |
| "For its numerous abilities including sedation, we have been using thalidomide (TH) as the 'last therapeutic option' in patients with advanced gliomas." | 3.81 | Thalidomide as palliative treatment in patients with advanced secondary glioblastoma. ( Ackerl, M; Dieckmann, KU; Flechl, B; Hainfellner, JA; Hassler, MR; Marosi, C; Prayer, D; Preusser, M; Rössler, K; Sax, C; Woehrer, A, 2015) |
| "Human malignant glioma cells U251-MG were cultured and assigned to four groups with different treatments for 3 days: temozolomide group (100 micromol/L), thalidomide group (100 microg/L), temozolomide (100 micromol/L) plus thalidomide group (100 microg/L) and control group." | 3.75 | Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. ( Gao, S; Ji, YW; Pan, Q; Yang, XJ; Zhang, WG, 2009) |
| "The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma." | 3.73 | Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006) |
| "Serial MR imaging was performed in 18 consecutive patients with recurrent malignant gliomas receiving both thalidomide and carboplatin for 12-month periods." | 3.70 | Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. ( Cha, S; Glass, J; Gruber, ML; Johnson, G; Knopp, EA; Litt, A; Lu, S; Zagzag, D, 2000) |
| "Malignant gliomas are tumors with a very unfavorable prognosis." | 1.43 | Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas. ( Kramm, CM; Kühnöl, CD; Staege, MS, 2016) |
| "Gliomas are highly vascularized tumors, suggesting that the prevention of vessel formation by anti-angiogenic treatment might be effective." | 1.40 | Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. ( Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D, 2014) |
| "Thalidomide treatment also dramatically suppressed the anchorage-independent growth of U-87 MG and other glioma cells by over a thousand fold without affecting its anchorage-dependent growth, which may be accomplished by knocking down endogenous bFGF expression in these cells." | 1.35 | The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma. ( Mei, SC; Wu, RT, 2008) |
| "Thalidomide is a racemate with known pharmacologic and pharmacokinetic enantioselectivity." | 1.34 | Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. ( Boyle, FM; Davey, RA; Gu, XQ; Mather, LE; Murphy, S, 2007) |
| "Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies." | 1.33 | Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006) |
| "Thalidomide has been previously shown to inhibit angiogenesis induced by basic fibroblast growth factor in vivo, using the rabbit corneal micropocket assay." | 1.30 | Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. ( Friedlander, DR; Kaplan, G; Moreira, AL; Shif, B; Zagzag, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 13 (50.00) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yung, R | 1 |
| Seyfoddin, V | 1 |
| Guise, C | 1 |
| Tijono, S | 1 |
| McGregor, A | 1 |
| Connor, B | 1 |
| Ching, LM | 1 |
| Porkholm, M | 1 |
| Valanne, L | 2 |
| Lönnqvist, T | 2 |
| Holm, S | 1 |
| Lannering, B | 1 |
| Riikonen, P | 2 |
| Wojcik, D | 1 |
| Sehested, A | 1 |
| Clausen, N | 1 |
| Harila-Saari, A | 1 |
| Schomerus, E | 1 |
| Thorarinsdottir, HK | 1 |
| Lähteenmäki, P | 1 |
| Arola, M | 1 |
| Thomassen, H | 1 |
| Saarinen-Pihkala, UM | 2 |
| Kivivuori, SM | 2 |
| Hassler, MR | 1 |
| Sax, C | 1 |
| Flechl, B | 1 |
| Ackerl, M | 1 |
| Preusser, M | 1 |
| Hainfellner, JA | 1 |
| Woehrer, A | 1 |
| Dieckmann, KU | 1 |
| Rössler, K | 1 |
| Prayer, D | 1 |
| Marosi, C | 1 |
| Milanovic, D | 1 |
| Sticht, C | 1 |
| Röhrich, M | 1 |
| Maier, P | 1 |
| Grosu, AL | 1 |
| Herskind, C | 1 |
| Kuramitsu, S | 1 |
| Ohno, M | 1 |
| Ohka, F | 1 |
| Shiina, S | 1 |
| Yamamichi, A | 1 |
| Kato, A | 1 |
| Tanahashi, K | 1 |
| Motomura, K | 1 |
| Kondo, G | 1 |
| Kurimoto, M | 1 |
| Senga, T | 1 |
| Wakabayashi, T | 1 |
| Natsume, A | 1 |
| Kühnöl, CD | 1 |
| Staege, MS | 1 |
| Kramm, CM | 1 |
| Shimizu, T | 1 |
| Kurozumi, K | 2 |
| Ishida, J | 1 |
| Ichikawa, T | 2 |
| Date, I | 2 |
| Mei, SC | 1 |
| Wu, RT | 1 |
| Gao, S | 1 |
| Yang, XJ | 1 |
| Zhang, WG | 1 |
| Ji, YW | 1 |
| Pan, Q | 1 |
| Onishi, M | 1 |
| Ruiz, J | 1 |
| Case, D | 1 |
| Enevold, G | 1 |
| Rosdhal, R | 1 |
| Tatter, SB | 1 |
| Ellis, TL | 1 |
| McQuellon, RP | 1 |
| McMullen, KP | 1 |
| Stieber, VW | 1 |
| Shaw, EG | 1 |
| Lesser, GJ | 1 |
| Giglio, P | 1 |
| Dhamne, M | 1 |
| Hess, KR | 1 |
| Gilbert, MR | 1 |
| Groves, MD | 1 |
| Levin, VA | 2 |
| Kang, SL | 1 |
| Ictech, SE | 1 |
| Liu, V | 1 |
| Colman, H | 1 |
| Conrad, CA | 1 |
| Loghin, M | 1 |
| de Groot, J | 1 |
| Yung, WK | 2 |
| Puduvalli, VK | 1 |
| Fine, HA | 2 |
| Wen, PY | 3 |
| Maher, EA | 1 |
| Viscosi, E | 1 |
| Batchelor, T | 1 |
| Lakhani, N | 1 |
| Figg, WD | 2 |
| Purow, BW | 1 |
| Borkowf, CB | 1 |
| Takano, S | 1 |
| Son, MJ | 1 |
| Kim, JS | 1 |
| Kim, MH | 1 |
| Song, HS | 1 |
| Kim, JT | 2 |
| Kim, H | 1 |
| Shin, T | 1 |
| Jeon, HJ | 1 |
| Lee, DS | 1 |
| Park, SY | 1 |
| Kim, YJ | 1 |
| Kim, JH | 1 |
| Nam, DH | 2 |
| Lee, JI | 1 |
| Itasaka, S | 1 |
| Turner, CD | 1 |
| Chi, S | 1 |
| Marcus, KJ | 1 |
| MacDonald, T | 1 |
| Packer, RJ | 1 |
| Poussaint, TY | 1 |
| Vajapeyam, S | 1 |
| Ullrich, N | 1 |
| Goumnerova, LC | 1 |
| Scott, RM | 1 |
| Briody, C | 1 |
| Chordas, C | 1 |
| Zimmerman, MA | 1 |
| Kieran, MW | 1 |
| Murphy, S | 1 |
| Boyle, FM | 1 |
| Davey, RA | 1 |
| Gu, XQ | 1 |
| Mather, LE | 1 |
| Kesari, S | 1 |
| Schiff, D | 1 |
| Doherty, L | 1 |
| Gigas, DC | 1 |
| Batchelor, TT | 1 |
| Muzikansky, A | 1 |
| O'Neill, A | 1 |
| Drappatz, J | 1 |
| Chen-Plotkin, AS | 1 |
| Ramakrishna, N | 1 |
| Weiss, SE | 1 |
| Levy, B | 1 |
| Bradshaw, J | 1 |
| Kracher, J | 1 |
| Laforme, A | 1 |
| Black, PM | 2 |
| Folkman, J | 1 |
| Kieran, M | 1 |
| Burton, E | 1 |
| Prados, M | 1 |
| Moreira, AL | 1 |
| Friedlander, DR | 1 |
| Shif, B | 1 |
| Kaplan, G | 1 |
| Zagzag, D | 2 |
| Jaeckle, K | 1 |
| Kyritsis, AP | 1 |
| Loeffler, JS | 1 |
| Kaplan, R | 1 |
| Pluda, JM | 1 |
| Cha, S | 1 |
| Knopp, EA | 1 |
| Johnson, G | 1 |
| Litt, A | 1 |
| Glass, J | 1 |
| Gruber, ML | 1 |
| Lu, S | 1 |
| Cohen, MH | 1 |
| Short, SC | 1 |
| Traish, D | 1 |
| Dowe, A | 1 |
| Hines, F | 1 |
| Gore, M | 1 |
| Brada, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas[NCT00047879] | Phase 2 | 7 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00047879)
Timeframe: 4 months
| Intervention | Participants (Number) |
|---|---|
| Glioblastoma Multiforme Stratum | 4 |
| Anaplastic Glioma Stratum | 2 |
4 reviews available for thalidomide and Glial Cell Tumors
| Article | Year |
|---|---|
Adhesion molecules and the extracellular matrix as drug targets for glioma.
Topics: Angiogenesis Inhibitors; Antibodies; Brain Neoplasms; Cell Adhesion Molecules; Disease Progression; | 2016 |
Angiogenesis and invasion in glioma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevaciz | 2011 |
[Anti-angiogenesis treatment for brain tumors--present and future].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Tr | 2005 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; | 1999 |
7 trials available for thalidomide and Glial Cell Tumors
| Article | Year |
|---|---|
A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Female; Follow-Up Studies; G | 2012 |
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; | 2012 |
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2003 |
Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme.
Topics: Adolescent; Angiogenesis Inhibitors; Brain Stem Neoplasms; Child; Combined Modality Therapy; Disease | 2007 |
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2007 |
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality T | 2000 |
Thalidomide as an anti-angiogenic agent in relapsed gliomas.
Topics: Adult; Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Glioma; Humans; Middle Aged; N | 2001 |
15 other studies available for thalidomide and Glial Cell Tumors
| Article | Year |
|---|---|
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Mode | 2014 |
Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Case-Control Studi | 2014 |
Thalidomide as palliative treatment in patients with advanced secondary glioblastoma.
Topics: Adult; Antineoplastic Agents; Female; Glioblastoma; Glioma; Humans; Male; Palliative Care; Retrospec | 2015 |
Inhibition of 13-cis retinoic acid-induced gene expression of reactive-resistance genes by thalidomide in glioblastoma tumours in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2015 |
Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; ErbB Receptors; Glioma; Humans; Immunologic Fa | 2015 |
Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas.
Topics: Antineoplastic Agents; Dendritic Cells; Drug Screening Assays, Antitumor; Glioma; Humans; Immunologi | 2016 |
The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma.
Topics: Angiogenesis Inhibitors; Brain Neoplasms; Fibroblast Growth Factor 2; Glioma; Guanine; Humans; Promo | 2008 |
Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gli | 2009 |
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neop | 2011 |
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2006 |
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality | 2006 |
Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 2007 |
Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro.
Topics: Animals; Cell Division; Cornea; Endothelium, Vascular; Fibroblast Growth Factor 2; Glioma; Humans; N | 1999 |
Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Echo-Plan | 2000 |
Thalidomide in the treatment of high-grade gliomas.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase II as Topic; Glioma; Humans; Middle Aged; Thalidomid | 2000 |